3-[benzyloxycarbonylamino]-2,2-dimethylpropanoic acid,methyl ester

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-[benzyloxycarbonylamino]-2,2-dimethylpropanoic acid,methyl ester
• 英文别名: methyl 3-benzyloxycarbonylamino-2,2-dimethylpropionate；Methyl 3-(((benzyloxy)carbonyl)amino)-2,2-dimethylpropanoate；methyl 2,2-dimethyl-3-(phenylmethoxycarbonylamino)propanoate
• 化学式: C₁₄H₁₉NO₄
• 分子量: 265.309
• InChiKey: AHIPMRUJNVVTFN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-[benzyloxycarbonylamino]-2,2-dimethylpropanoic acid,methyl ester 生成 3-(苄氧基羰基氨基)-2,2-二甲基丙酸
  参考文献：
  名称：

  Benzo-fused lactams that promote the release of growth hormone

  摘要：

  已披露了一些新型化合物，被确定为苯并咪唑内酰胺，可促进人类和动物体内生长激素的释放。这种特性可以用于促进食用动物的生长，使可食用肉制品的生产更加高效，在人类身上，可以增加那些缺乏正常分泌天然生长激素的人的身高。还披露了含有苯并咪唑内酰胺作为活性成分的促生长组合物。

  公开号：

  US05206235A1
• 作为产物：
  描述：

  二苯基膦叠氮化物 以 甲苯 为溶剂， 生成 3-[benzyloxycarbonylamino]-2,2-dimethylpropanoic acid,methyl ester
  参考文献：
  名称：

  Angiotensinogen analogs

  摘要：

  该发明涉及以下结构的肾素抑制化合物##STR1##其中A为氢；较低烷基；芳基烷基；OR.sub.10或SR.sub.10，其中R.sub.10为氢，较低烷基或氨基烷基；NR.sub.11 R.sub.12，其中R.sub.11和R.sub.12分别选择自氢，较低烷基，氨基烷基，氰基烷基和羟基烷基；##STR2##其中B为NH，烷基氨基，S，O，CH.sub.2或CHOH，R.sub.13为较低烷基，环烷基，芳基，芳基烷基，烷氧基，烯基氧基，羟基烷氧基，二羟基烷氧基，芳基烷氧基，芳基烷氧基烷基，氨基，烷基氨基，二烷基氨基，(羟基烷基)(烷基)氨基，(二羟基烷基)(烷基)氨基，氨基烷基，烷氧羰基烷基，羧基烷基，N-保护氨基烷基，烷基氨基烷基，(N-保护)(烷基)氨基烷基，二烷基氨基烷基，(杂环)烷基或取代或未取代的杂环；W为CO或CHOH，U为CH.sub.2或NR.sub.2，但当W为CHOH时，U为CH.sub.2；R.sub.1为较低烷基，环烷基甲基，苄基，.alpha.，.alpha.-二甲基苄基，4-甲氧基苄基，卤代苄基，(1-萘基)甲基，(2-萘基)甲基，(4-咪唑基)-甲基，苯乙基，苯氧基，噻吩氧基或苯胺基；但如果R.sub.1为苯氧基，噻吩氧基或苯胺基，B为CH.sub.2或CHOH或A为氢，R.sub.3为较低烷基，烯基较低烷基，苄基或杂环环取代甲基，R.sub.5为较低烷基，环烷基甲基或苄基；R.sub.2和R.sub.4分别选择自氢和较低烷基；R.sub.6为CHOH或CO；R.sub.7为CH.sub.2，CF.sub.2或CF，但当R.sub.6为CO时，R.sub.7为CF.sub.2；R.sub.8为CH.sub.2，CHR.sub.14，其中R.sub.14为较低烷基，环烷基，环烷基烷基，芳基或芳基烷基，或R.sub.7和R.sub.8一起可以是##STR3##但当R.sub.7为CF.sub.2时，R.sub.8为CH.sub.2；E为O，S，SO，SO.sub.2，NR.sub.15，其中R.sub.15为氢或较低烷基或NR.sub.16 CO，其中R.sub.16为氢或较低烷基；R.sub.9为较低烷基，环烷基，环烷基烷基，芳基，芳基烷基或N-保护基，或E和R.sub.9一起可以是N.sub.3，但当E为NH时，R.sub.9为N-保护基；及其药学上可接受的盐。

  公开号：

  US04857507A1

文献信息

• A Potent, Orally Bioavailable Benzazepinone Growth Hormone Secretagogue
  作者：Robert J. DeVita、Richard Bochis、Alison J. Frontier、Andrew Kotliar、Michael H. Fisher、William R. Schoen、Matthew J. Wyvratt、Kang Cheng、Wanda W.-S. Chan、Bridget Butler、Thomas M. Jacks、Gerard J. Hickey、Klaus D. Schleim、Kwan Leung、Zhesheng Chen、S.-H. Lee Chiu、William P. Feeney、Paul K. Cunningham、Roy G. Smith

  DOI：10.1021/jm970816j

  日期：1998.5.1

  identification of L-739,943 (8b), a potent, orally bioavailable benzolactam growth hormone secretagogue, is obtained from zwitterionic L-692,429 through modification of its amino acid side chain and replacement of the acidic 2'-tetrazole with the neutral and potency enhancing 2'-(N-methylaminocarbonylamino)methyl substituent. L-739,943 is orally active for the release of growth hormone in beagle dogs at doses

  L-739,943（8b）是一种有效的，口服可生物利用的苯并内酰胺生长激素促分泌素的鉴定产品，是通过两性离子L-692,429的氨基酸侧链修饰和酸性2'-四唑的中性和效价增强而获得的2'-（N-甲基氨基羰基氨基）甲基取代基。L-739,943口服活性低至0.5 mg / kg，可在比格犬中释放生长激素。剂量为2 mg / kg时，狗8b的口服生物利用度为24％，平均药物Cmax为145 +/- 46 ng / mL。与原型苯并内酰胺L-692,429相比，L-739,943在效能和口服生物利用度方面均取得了重大突破。
• Angiotensinogen analogs
  申请人：Abbott Laboratories

  公开号：US04857507A1

  公开（公告）日：1989-08-15

  The invention relates to renin inhibiting compounds of the formula ##STR1## wherein A is hydrogen; loweralkyl; arylalkyl; OR.sub.10 or SR.sub.10 wherein R.sub.10 is hydrogen, loweralkyl or aminoalkyl; NR.sub.11 R.sub.12 wherein R.sub.11 and R.sub.12 are independently selected from hydrogen, loweralkyl, aminoalkyl, cyanoalkyl and hydroxyalkyl; ##STR2## wherein B is NH, alkylamino, S, O, CH.sub.2 or CHOH and R.sub.13 is loweralkyl, cycloalkyl, aryl, arylalkyl, alkoxy, alkenyloxy, hydroxyalkoxy, dihydroxyalkoxy, arylalkoxy, arylalkoxyalkyl, amino, alkylamino, dialkylamino, (hydroxyalkyl)(alkyl)amino, (dihydroxyalkyl)(alkyl)amino, aminoalkyl, alkoxycarbonylalkyl, carboxyalkyl, N-protected aminoalkyl, alkylaminoalkyl, (N-protected)(alkyl)aminoalkyl, dialkylaminoalkyl, (heterocyclic) alkyl or a substituted or unsubstituted heterocyclic; W is CO or CHOH and U is CH.sub.2 or NR.sub.2 with the proviso that when W is CHOH then U is CH.sub.2 ; R.sub.1 is loweralkyl, cycloaklylmethyl, benzyl, .alpha.,.alpha.-dimethylbenzyl, 4-methoxybenzyl, halobenzyl, (1-naphthyl)methyl, (2-naphthyl)methyl, (4-imidazoyl)-methyl, phenethyl, phenoxy, thiophenoxy or anilino; provided if R.sub.1 is phenoxy, thiophenoxy or anilino, B is CH.sub.2 or CHOH or A is hydrogen, R.sub.3 is loweralkyl, vinylloweralkyl, benzyl or heterocyclic ring substituted methyl, R.sub.5 is loweralkyl, cycloalkylmethyl or benzyl; R.sub.2 and R.sub.4 are independently selected from hydrogen and loweralkyl; R.sub.6 is CHOH or CO; R.sub.7 is CH.sub.2, CF.sub.2 or CF with the proviso that when R.sub.6 is CO, R.sub.7 is CF.sub.2 ; R.sub.8 is CH.sub.2, CHR.sub.14 wherein R.sub.14 is lower-alkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl, or R.sub.7 and R.sub.8 taken together can be ##STR3## with the proviso that when R.sub.7 is CF.sub.2, R.sub.8 is CH.sub.2 ; E is O, S, SO, SO.sub.2, NR.sub.15 wherein R.sub.15 is hydrogen or loweralkyl or NR.sub.16 CO wherein R.sub.16 is hydrogen or loweralkyl; R.sub.9 is loweralkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or an N-protected group, or E and R.sub.9 taken together can be N.sub.3, with the proviso that when E is NH, R.sub.9 is an N-protecting group; and pharmaceutically acceptable salts thereof.

  该发明涉及以下结构的肾素抑制化合物##STR1##其中A为氢；较低烷基；芳基烷基；OR.sub.10或SR.sub.10，其中R.sub.10为氢，较低烷基或氨基烷基；NR.sub.11 R.sub.12，其中R.sub.11和R.sub.12分别选择自氢，较低烷基，氨基烷基，氰基烷基和羟基烷基；##STR2##其中B为NH，烷基氨基，S，O，CH.sub.2或CHOH，R.sub.13为较低烷基，环烷基，芳基，芳基烷基，烷氧基，烯基氧基，羟基烷氧基，二羟基烷氧基，芳基烷氧基，芳基烷氧基烷基，氨基，烷基氨基，二烷基氨基，(羟基烷基)(烷基)氨基，(二羟基烷基)(烷基)氨基，氨基烷基，烷氧羰基烷基，羧基烷基，N-保护氨基烷基，烷基氨基烷基，(N-保护)(烷基)氨基烷基，二烷基氨基烷基，(杂环)烷基或取代或未取代的杂环；W为CO或CHOH，U为CH.sub.2或NR.sub.2，但当W为CHOH时，U为CH.sub.2；R.sub.1为较低烷基，环烷基甲基，苄基，.alpha.，.alpha.-二甲基苄基，4-甲氧基苄基，卤代苄基，(1-萘基)甲基，(2-萘基)甲基，(4-咪唑基)-甲基，苯乙基，苯氧基，噻吩氧基或苯胺基；但如果R.sub.1为苯氧基，噻吩氧基或苯胺基，B为CH.sub.2或CHOH或A为氢，R.sub.3为较低烷基，烯基较低烷基，苄基或杂环环取代甲基，R.sub.5为较低烷基，环烷基甲基或苄基；R.sub.2和R.sub.4分别选择自氢和较低烷基；R.sub.6为CHOH或CO；R.sub.7为CH.sub.2，CF.sub.2或CF，但当R.sub.6为CO时，R.sub.7为CF.sub.2；R.sub.8为CH.sub.2，CHR.sub.14，其中R.sub.14为较低烷基，环烷基，环烷基烷基，芳基或芳基烷基，或R.sub.7和R.sub.8一起可以是##STR3##但当R.sub.7为CF.sub.2时，R.sub.8为CH.sub.2；E为O，S，SO，SO.sub.2，NR.sub.15，其中R.sub.15为氢或较低烷基或NR.sub.16 CO，其中R.sub.16为氢或较低烷基；R.sub.9为较低烷基，环烷基，环烷基烷基，芳基，芳基烷基或N-保护基，或E和R.sub.9一起可以是N.sub.3，但当E为NH时，R.sub.9为N-保护基；及其药学上可接受的盐。
• Renin inhibiting compounds
  申请人：Abbott Laboratories

  公开号：US04826815A1

  公开（公告）日：1989-05-02

  The invention relates to renin inhibiting compounds of the formula ##STR1## wherein A is hydrogen; loweralkyl; arylalkyl; Or.sub.10 wherein R.sub.10 is hydrogen or loweralkyl; NR.sub.11 R.sub.12 wherein R.sub.11 and R.sub.12 are independently selected from hydrogen and loweralkyl; or R.sub.13 --CO--B wherein B is NH, O, CH.sub.2, HNCH.sub.2 and R.sub.13 is loweralkyl, alkoxy, arylalkoxy, arylalkoxyalkyl, amino, alkylamino, dialkylamino, aminoalkyl, N-protected aminoalkyl, hydroxylated dialkylamino, (heterocyclic)alkyl or a substituted or unsubstituted heterocyclic, carboxyalkyl, or lower alkyl carboxyalkyl esters; W is N or CH: U,V may be the following combinations H,OH; OH,H; H,H; or when taken together as O represents a carbonyl with the provisos that if U,V.dbd.H,OH, then W=CH, and if U,V.dbd.O then W.dbd.N; R.sub.1 , R.sub.3 and R.sub.5 are loweralkyl or hydrophilic, lipophilic or aromatic amino acid side chains and may be the same or different; R.sub.2, R.sub.4, R.sub.7, R.sub.8 and R.sub.9 are hydrogen or loweralkyl and may be the same or different; X is NH, O, S, SO, SO.sub.2, or CH.sub.2 ; and R.sub.6 is loweralkyl cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or an N-protecting group, with the proviso that R.sub.6 may be an N-protecting group when X is NH.

  该发明涉及以下结构的抑制肾素化合物 ##STR1## 其中A为氢；loweralkyl；arylalkyl；Or.sub.10，其中R.sub.10为氢或loweralkyl；NR.sub.11 R.sub.12，其中R.sub.11和R.sub.12分别独立选择自氢和loweralkyl；或R.sub.13 --CO--B，其中B为NH，O，CH.sub.2，HNCH.sub.2，R.sub.13为loweralkyl，alkoxy，arylalkoxy，arylalkoxyalkyl，氨基，烷基氨基，二烷基氨基，氨基烷基，N-保护氨基烷基，羟基化的二烷基氨基，（杂环）烷基或取代或未取代的杂环，羧基烷基或lower alkyl羧基酯；W为N或CH；U,V可以是以下组合H,OH；OH,H；H,H；或当作为O一起取时表示一个羰基，但有条件是如果U,V=dbd.H,OH，则W=CH，如果U,V=dbd.O，则W=dbd.N；R.sub.1，R.sub.3和R.sub.5为loweralkyl或亲水性，亲脂性或芳香族氨基酸侧链，可以相同也可以不同；R.sub.2，R.sub.4，R.sub.7，R.sub.8和R.sub.9为氢或loweralkyl，可以相同也可以不同；X为NH，O，S，SO，SO.sub.2，或CH.sub.2；R.sub.6为loweralkyl环烷基，环烷基烷基，芳香族，芳基烷基或N-保护基，但有条件是当X为NH时R.sub.6可以是N-保护基。
• Functionalized peptidyl aminodiols and -triols
  申请人：Abbott Laboratories

  公开号：US04977277A1

  公开（公告）日：1990-12-11

  The invention relates to renin inhibiting compounds of the formula ##STR1## wherein A is hydrogen; loweralkyl; arylalkyl; OR.sub.8 or SR.sub.8 wherein R.sub.8 is hydrogen, loweralkyl or aminoalkyl; NR.sub.9 R.sub.10 wherein R.sub.9 and R.sub.10 are independently selected from hydrogen, loweralkyl, aminoalkyl, cyanoalkyl and hydroxyalkyl; ##STR2## wherein B is NH, alkylamino, S, O, CH.sub.2 or CHOH and R.sub.11 is loweralkyl, cycloalkyl, aryl, arylalkyl, alkoxy, alkenyloxy, hydroxyalkoxy, dihydroxyalkoxy, arylalkoxy, arylalkoxyalkyl, amino, alkylamino, dialkylamino, (hydroxyalkyl)(alkyl)amino, (dihydroxyalkyl)(alkyl)amino, carboxylic acid-substituted alkyl, alkoxycarbonylalkyl, aminoalkyl, N-protected aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (N-protected)-(alkyl)aminoalkyl, (heterocyclic)alkyl or a substituted or unsubstituted heterocyclic; R.sub.1 is loweralkyl, cycloalkylmethyl, benzyl, .alpha.-methylbenzyl, .alpha., .alpha.-dimethylbenzyl, 4-methoxybenzyl, halobenzyl, (1-naphthyl)-methyl, (2-naphthyl)methyl, (4-imidazoyl)methyl, phenethyl, phenoxy, thiophenoxy or anilino; provided if R.sub.1 is phenoxy, thiophenoxy or anilino, B is CH.sub.2 or CHOH or A is hydrogen; R.sub.3 is loweralkyl, benzyl or heterocyclic ring-substituted methyl; R.sub.4 is lower-alkyl, cycloalkyl- methyl or benzyl; R.sub.2, R.sub.5 and R.sub.6 are independently hydrogen or loweralkyl; X is O, NH or S; R.sub.7 is hydrogen, loweralkyl, alkanoyl, alkylsulfonyl ##STR3## wherein R.sub.12 and R.sub.13 are independently hydrogen or loweralkyl, n is 0-2 and R.sub.14 is substituted or unsubstituted phenyl or heterocyclic; or XR.sub.7 together are loweralkylsulfonyl, N.sub.3 or Cl, and pharmaceutically acceptable salts thereof.

  本发明涉及公式##STR1##的肾素抑制化合物，其中A为氢；低烷基；芳基烷基；OR.sub.8或SR.sub.8，其中R.sub.8为氢，低烷基或氨基烷基；NR.sub.9R.sub.10，其中R.sub.9和R.sub.10独立选择自氢，低烷基，氨基烷基，氰基烷基和羟基烷基；##STR2##其中B为NH，烷基氨基，S，O，CH.sub.2或CHOH，R.sub.11为低烷基，环烷基，芳基，芳基烷基，烷氧基，烯烃氧基，羟基烷氧基，二羟基烷氧基，芳基烷氧基，芳基烷氧基烷基，氨基，烷基氨基，二烷基氨基，（羟基烷基）（烷基）氨基，（二羟基烷基）（烷基）氨基，羧酸取代的烷基，烷氧羰基烷基，氨基烷基，N-保护氨基烷基，烷基氨基烷基，二烷基氨基烷基，（N-保护）-（烷基）氨基烷基，（杂环）烷基或取代或未取代的杂环；R.sub.1为低烷基，环烷基甲基，苯甲基，α-甲基苯甲基，α，α-二甲基苯甲基，4-甲氧基苯甲基，卤代苯甲基，（1-萘基）-甲基，（2-萘基）-甲基，（4-咪唑基）-甲基，苯乙基，苯氧基，噻吩氧基或苯胺基；但如果R.sub.1为苯氧基，噻吩氧基或苯胺基，则B为CH.sub.2或CHOH或A为氢；R.sub.3为低烷基，苯甲基或杂环环取代甲基；R.sub.4为低烷基，环烷基甲基或苯甲基；R.sub.2，R.sub.5和R.sub.6独立地为氢或低烷基；X为O，NH或S；R.sub.7为氢，低烷基，烷酰基，烷基磺酰基##STR3##其中R.sub.12和R.sub.13独立地为氢或低烷基，n为0-2，R.sub.14为取代或未取代的苯基或杂环；或XR.sub.7一起为低烷基磺酰基，N.sub.3或Cl，以及其药学上可接受的盐。
• PEPTIDE ANALOGS
  申请人：DELLARIA, Joseph

  公开号：EP0258289A1

  公开（公告）日：1988-03-09